Qingfeng Biochem Secures Tens of Millions in Pre-A Funding from Baiyun Fund to Accelerate AI-Powered Smart Laboratory Development

Recently, GentleFlow Biochemical Technology (Guangzhou) Co., Ltd. (“GentleFlow”) announced the completion of its Pre-A financing round, raising tens of millions of RMB. This round was exclusively invested by Baiyun Fund, a subsidiary of Baiyun Financial Holdings. This investment represents a strategic move by Baiyun Financial Holdings to empower the development of strategic emerging industries. The funds will primarily be used to accelerate the deployment of AI-driven laboratory automation, including capacity expansion, research and development of the large AI models BioFlow AI and Supervisor AI, construction of the UBLab Unattended Application Center, and application development of the OutStanding large-scale automation integration platform.

‌

Gentleflow, established in 2018, is a hard-tech innovation enterprise with fully independent core technologies, specializing in the R&D, manufacturing, and sales of high-end automated life science equipment, platforms, related modules, and consumables.

Currently, life science research is entering the “The New Era of Efficiency Competition”, high-throughput experimentation and precision operations have become core demands in the scientific research field. However, in the critical sector of high-end laboratory automation equipment, imported brands have long held over 95% of the market share. Confronting this industry dilemma, Gentleflow Biochem, leveraging its independently developed and commercially deliveredOutStanding Large-Scale Automated Liquid Handling WorkstationIntegrated Platform‌, successfully breaking the foreign technological monopoly. Characterized by high-flexibility integration, modularity, and standardized design, the platform supports “multi-functionality in a single unit” and covers diverse life science application scenarios. It effectively addresses industry pain points associated with traditional non-standard customization, such as long delivery cycles and difficulties in achieving mass production.

The core of the large-scale liquid handling workstation integration platform lies in “Dual Liquid Level Detection, Non-Uniform Spacing, Flexible 8-Channel Pipetting Module”, this technology is the key to expanding into more application scenarios. There is often a significant gap between technological development and commercial implementation. Leveraging its profound insights into application scenarios, top-tier R&D capabilities, and efficient execution, Gentleflow successfully bridged this gap in 2025, sequentially delivering products to national key research institutions, government departments, and leading biotechnology enterprises.

Notably, in 2025Gentleflow successfully won the bid for a large-scale pipetting workstation project with a unit value of nearly RMB 2 million, becoming the first domestic company to defeat imported brands in this price segment.Marking a critical step in the domestic substitution of high-end laboratory automation equipment. Baiyun Fund’s exclusive investment this time will further help the enterprise deepen technology transfer and industrial implementation.

In December 2025, the “Life Science Intelligent Manufacturing Innovation Center,” spearheaded by Gentleflow Biochemical, was included in Guangzhou’s list of municipal-level manufacturing innovation centers under preparation (48 centers citywide). The center will align with Guangzhou’s “12218” modern industrial system, focus on strategic industrial clusters, conduct R&D on key generic technologies, promote collaborative innovation among industry, academia, and research institutions, and facilitate technology transfer and talent development.

In January 2025, the prestigious international journal Nature listed seven noteworthy technologies for the year, with “Self-driving Labs” making the cut. The integration of automation and artificial intelligence is regarded as a “productivity amplifier.” Following this round of financing from Baiyun Fund, gentleflow will further advance the construction of its “AI + Automation” closed-loop system, enabling equipment to leap from mechanical execution to intelligent response.

It is reported that the company’s self-developed BioFlow AI handles “instruction translation,” converting scientists’ natural language into executable experimental requirements, while Supervisor AI focuses on experimental data governance and protocol optimization, enabling smarter and more efficient experimental processes.

Baiyun Fund is a private equity investment firm registered with the Asset Management Association of China. Established in August 2017 with a registered capital of RMB 200 million, the company focuses on private equity investment (VC/PE) and is committed to building a diversified and comprehensive corporate financial services ecosystem. To date, its total assets under management have exceeded RMB 8.048 billion, with 62 cumulative investments made and 54 portfolio companies currently active.